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ABSTRACT The important role of CD8+ T-cells in the pathogenesis of psoria-
sis is well-determined. However, besides type 1 cytokines that were formerly 
known, it was recently found that these cells secrete type 17 and type 22 cy-
tokines. The majority of IL-17A+CD8+ T-cells in the blood belong to a subset of 
innate T-cells named mucosa-associated invariant T-cells (MAIT). However, the 
majority of IL-17A+CD8+ T-cells in psoriatic epidermis are conventional T-cells 
and are up-regulated in psoriasis. In contrast to Th17 cells that secrete only IL-
17, Tc17 cells secrete IFN-ϒ, TNF-α, CCL20, IL-22, and granzyme B as well. The 
key cytokine is IL-17A, which promotes keratinocyte hyperproliferation and 
stimulates them to produce other proinflammatory cytokines. These activities 
initiate and propagate the inflammation and architectural changes in the skin 
that clinically manifest as psoriatic lesions. However, a relatively novel cell sub-
type named Tc22 has been discovered in psoriasis that could secrete IL-22 in 
the absence of IL-17 and IFN-gamma. IL-22 stimulates proliferation and de-dif-
ferentiation of keratinocytes, subsequently leading to epidermal acanthosis. As 
the understanding of the pathogenesis of psoriasis increases, the new selective 
therapies may offer an optimal balance between increased clinical benefit and 
reduced risk of side-effects.
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INTROdUCTION
Psoriasis is a chronic, immunologically mediated 
skin disease that affects approximately 2-3% of the 
world’s population (1). It may cause significant mor-
bidity due to the possible co-existence with psoriatic 
arthritis and association with a large number of sys-
temic diseases (1). The most common manifestation 
is chronic plaque psoriasis but other forms like gut-
tate, pustular, or erythrodermic may also be present 
(1). The exact triggering agents are not fully recog-
nized yet, but it is known that genetic, environmen-
tal, and immunological factors participate in psoriasis 
pathogenesis (2,3). 
Despite the obvious involvement of innate im-
munity in psoriasis pathogenesis, it is commonly be-
lieved that T-cells and cytokines play a central role (4). 
While CD8+ T-cells are predominantly found in the 
epidermis, CD4+ T-cells are located in the upper der-
mis of psoriatic skin lesions (5,6).
For a long time, psoriasis was considered a Th1-
mediated skin disease (7). However, an important 
advancement in understanding the pathogenesis of 
this complex disease was discovery of T-helper type 
17 (Th17) cells and very recently of T-helper type 22 
or Th22 cells (7). Despite CD4+ T-lymphocytes, cyto-
toxic CD8+ T-cells are also capable of producing cyto-
kines such as IL-2, IFN-gamma, TNF-alpha, IL-17, and 
the IL-22 cytokine family (8). They are consecutively 
named Tc1, Tc17, and Tc22 cells, and the knowledge 
of their involvement in psoriasis has been growing 
recently (Figure 1) (8).
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Tc1 LYMPHOCYTE POPULATION IN  
PSORIASIS
Generally, there are subsets of CD8+ T-cells that are 
similar to their CD4+ counterparts (8,9). Analogous to 
the Th1/Th2 terminology and depending on the cy-
tokines they produce, these two subsets were termed 
Tc1 and Tc2 (8,9). In psoriasis, Tc1 cells are activated, 
produce cytokines such as IFN-gamma, IL-2, and TNF-
alpha, and play an important role in the inflammatory 
process (9). For a long time Tc1 cells were thought to 
be main CD8+ subset in CD8 cytokine production 
(9,10). 
Most of Tc1 cells isolated from psoriatic lesions 
produce IFN-γ (11). Serum levels of CD8+IFN-γ+ T-
cells in the blood of patients correlate with psoriasis 
disease severity (12). The main effects of IFN-γ are ac-
tivating keratinocytes and antigen-presenting cells 
early in the psoriatic cascade to produce IL-1β and 
IL-22, thus promoting the cytokine storm in psoriasis 
(12). However, because of the failure of an IFN-γ tar-
geted therapy and discovery of other cytokines, the 
role of IFN-γ in the pathogenesis of psoriasis is not 
crucial as previously believed (12). 
The main function of TNF-α in psoriasis is regu-
lation of antigen-presenting cells (13). It also stimu-
lates the secretion of other cytokines such as IL-23 
from dendritic cells (14). TNF-α alone does not lead 
to significant response of cultured keratinocytes, but 
it forms strong synergies with other cytokines such as 
IL-17A and subsequently amplifies the immunologic 
cascade (12). TNF-α is also capable of stimulating pro-
liferation and chemotaxis of T-cells to the site of the 
lesion, with the mediation of CXCL-10 through regu-
lation of the adhesion molecules in the endothelial 
cells (13).
Tc17 LYMPHOCYTE POPULATION IN  
PSORIASIS
The oligoclonal Tc17 cells infiltrate the lesional 
epidermis (15). They may be activated by Th17 cells or 
may infiltrate after recognition of autoantigens in the 
context of MHC class I (15). The influx of Tc17 T cells 
significantly correlates with the disease severity (15).
The predominant IL-17A-producing CD8+ T-cells 
in psoriatic lesions are conventional CD8+ T-cells that 
generally predominate in psoriatic skin (15). How-
ever, it has been reported that the vast majority of 
Tc17 cells in peripheral blood are mucosa-associated 
invariant T-cells (MAIT cells) (15,16). MAIT cells belong 
to the innate immune system and express an invari-
ant TCR α-chain for recognition of bacterial ligands 
in the context of MR1, a MHC class I-like antigen-pre-
senting molecule (15,16). They secrete IL-17, but not 
exclusively (15,16). IL-17A-producing CD8+ MAIT cells 
Figure 1. Roles of Tc1, Tc17, and Tc22 cells in the pathogenesis of psoriasis. 
Legend: Tc1: cytotoxic lymphocyte type 1; Tc17: cytotoxic lymphocyte type 17; Tc22: cytotoxic lymphocyte type 22; IL: inter-
leukin; IFN: interferon; TNF: tumor necrosis factor; APC: antigen presenting cell; Kc: keratinocyte
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were found in psoriatic skin as well (15,16). Contrary 
to Th17 cells that secrete only IL-17, Tc17 cells secrete 
IFN-γ, TNF-α, CCL20, and granzyme B as well (17). 
Furthermore, Tc17 cells express CCR6, the ligand for 
CCL20, and it seems to be crucial for epidermal hom-
ing of all CD8+ cells (17). 
The IL-17 family consists of 6 members, namely 
IL-17A to IL-17F (18). They bind five different types of 
receptor subunits, IL-17RA to IL-17RE (18). The most 
active IL-17 cytokines in psoriasis are IL-17A and IL-
17F (7). IL-17A is about 10-30 times more potent than 
IL-17F, and so plays a key role in the pathogenesis of 
psoriasis (19). Elevated levels of IL-17A have been mea-
sured in psoriatic lesions compared with nonlesional 
tissue (20). IL-17A activates keratinocytes, activates 
and recruits neutrophils, and promotes the release 
of other inflammatory cytokines (18). It also stimu-
lates the expression of keratinocyte chemokines such 
as CCL20 that subsequently mediate recruitment of 
Th17 cells and dendritic cells to skin, and CXCL 1, 3, 
5, 6, and 8 that drive neutrophil recruitment (19). It 
also increases expression of antimicrobial peptides in 
psoriatic epidermis, including β-defensins and S100A 
family members (21). Effects of IL-17A depend on the 
local cytokine milieu, and overlap with other cyto-
kines present in psoriatic lesions (19).
Despite cytokine production, CD8+IL-17+ cells 
could produce cytotoxic molecules in psoriatic 
plaques such as granzyme B and kill target cells in 
a TCR/CD3-dependent manner (17). These mecha-
nisms require the coordinated expression of NKG2C 
and NKG2D on CD8+ T-cells, which are not detected 
in psoriatic CD8+ T-cells (17). Therefore, the precise 
mechanism of cytotoxic target cell killing in psoriasis 
is still to be elucidated.
Besides IL-17, Tc17 cells could secrete IL-22 that 
has keratinocyte proliferation-promotion capacity 
and is consequently responsible for the induction of 
acanthosis as well as production of antimicrobial pep-
tides by keratinocytes (22). IL-22mRNA expression is 
up-regulated in psoriatic skin lesions compared with 
healthy skin (22). Whereas Th17 cells do not expand 
in the lesional skin, Tc17 cells that could secrete IL-
17A alone or in combination with IL-22 are the key 
IL-17-producing cells in psoriatic skin (22).
Tc22 LYMPHOCYTE POPULATION IN  
PSORIASIS
Another CD8+ cell population recently deter-
mined in psoriasis are Tc22 cells (23). They are found 
in the epidermis of psoriatic skin in much higher 
numbers than in the adjacent dermis (22). Together 
with Tc17, they are a main source of IL-22 (23). Th22 
from lesional psoriatic skin secrete IL-22 in the ab-
sence of IL-17 and IFN-gamma, therefore producing 
only IL-22 (22). A concrete explanation for this phe-
nomenon is still lacking. However, it is presumed that 
those cells derived from Th17 and Tc17 cells that lose 
their capacity to express IL-17A and develop into 
IL-22 single-producing T-cells (22). As we already 
mentioned IL-22 stimulates proliferation and de-dif-
ferentiation of keratinocytes through the activation 
of the STAT3 signaling pathway that subsequently 
leads to epidermal acanthosis (23). It also promotes 
keratinocytes to produce chemokines such as CXCL8 
and CXCL1 (23). 
CONCLUSION
Psoriasis is a complex immune-mediated skin 
disease that clinically presents with inflammatory 
plaques on the skin. Today, there is considerable ex-
perimental and clinical evidence supporting a role 
of T-cells in the pathogenesis of psoriasis. Although 
there is much evidence that supports the theory that 
psoriasis is a Th17-mediated disease, recent studies 
have demonstrated the important role of Tc1, Tc17, 
and Tc22 cells. These cells produce an array of cyto-
kines that results in keratinocyte and vascular re-
sponse changes. It is a relatively unexplored research 
avenue in psoriasis but offers considerable promise as 
a possible approach to efficient and safe treatment of 
psoriasis. Further research should reveal new targets 
in the pathogenesis of psoriasis, so the new therapy 
with the least possible side-effects can be explored.
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